China's rapid rise creates 'heightened risks ' for pharma: PwC - Fierce Biotech
Analysts warned the evolution of Chinese biotech is creating “heightened risks related to IP security, regulatory compliance and strategic ...
Read the original at Fierce Biotech ↗
- Topics
- China & GeopoliticsRegulation & PolicyHealthcare
- Mentions
- China
- Tracked via
- “AI Risks”